Literature DB >> 16113282

Early cytokine production is associated with protection from murine cerebral malaria.

Andrew J Mitchell1, Anna M Hansen, Leia Hee, Helen J Ball, Sarah M Potter, John C Walker, Nicholas H Hunt.   

Abstract

Cerebral malaria (CM) is an infrequent but serious complication of Plasmodium falciparum infection in humans. Animal and human studies suggest that the pathogenesis of CM is immune mediated, but the precise mechanisms leading to cerebral pathology are unclear. In mice, infection with Plasmodium berghei ANKA results in CM on day 6 postinoculation (p.i.), while infection with the closely related strain P. berghei K173 does not result in CM. Infection with P. berghei K173 was associated with increased plasma gamma interferon (IFN-gamma) at 24 h p.i. and with increased splenic and hepatic mRNAs for a range of cytokines (IFN-gamma, interleukin-10 [IL-10], and IL-12) as well as the immunoregulatory enzyme indoleamine 2,3-dioxygenase. In contrast, P. berghei ANKA infection was associated with an absence of cytokine production at 24 h p.i. but a surge of IFN-gamma production at 3 to 4 days p.i. When mice were coinfected with both ANKA and K173, they produced an early cytokine response, including a burst of IFN-gamma at 24 h p.i., in a manner similar to animals infected with P. berghei K173 alone. These coinfected mice failed to develop CM. In addition, in a low-dose P. berghei K173 infection model, protection from CM was associated with early production of IFN-gamma. Early IFN-gamma production was present in NK-cell-depleted, gammadelta-cell-depleted, and Jalpha281(-/-) (NKT-cell-deficient) mice but absent from beta2-microglobulin mice that had been infected with P. berghei K173. Taken together, the results suggest that the absence of a regulatory pathway involving IFN-gamma and CD8(+) T cells in P. berghei ANKA infection allows the development of cerebral immunopathology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113282      PMCID: PMC1231146          DOI: 10.1128/IAI.73.9.5645-5653.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

Review 1.  Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways.

Authors:  D Jankovic; Z Liu; W C Gause
Journal:  Trends Immunol       Date:  2001-08       Impact factor: 16.687

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Mouse CD8+ CD122+ T cells with intermediate TCR increasing with age provide a source of early IFN-gamma production.

Authors:  E Takayama; S Seki; T Ohkawa; K Ami; Y Habu; T Yamaguchi; T Tadakuma; H Hiraide
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

4.  Cellular basis of early cytokine response to Plasmodium falciparum.

Authors:  M Hensmann; D Kwiatkowski
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

5.  Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens.

Authors:  G Lertmemongkolchai; G Cai; C A Hunter; G J Bancroft
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

6.  Early gamma interferon responses in lethal and nonlethal murine blood-stage malaria.

Authors:  J B De Souza; K H Williamson; T Otani; J H Playfair
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

Review 7.  Cerebral malaria: clinical features, pathophysiology and treatment.

Authors:  D A Warrell
Journal:  Ann Trop Med Parasitol       Date:  1997-10

8.  Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

9.  Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts.

Authors:  R T Gazzinelli; S Hieny; T A Wynn; S Wolf; A Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

10.  On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria.

Authors:  Elodie Belnoue; Michèle Kayibanda; Ana M Vigario; Jean-Christophe Deschemin; Nico van Rooijen; Mireille Viguier; Georges Snounou; Laurent Rénia
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

View more
  55 in total

1.  IRGM3 contributes to immunopathology and is required for differentiation of antigen-specific effector CD8+ T cells in experimental cerebral malaria.

Authors:  Jintao Guo; James A McQuillan; Belinda Yau; Gregory S Tullo; Carole A Long; Patrick Bertolino; Ben Roediger; Wolfgang Weninger; Gregory A Taylor; Nicholas H Hunt; Helen J Ball; Andrew J Mitchell
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

2.  Patent filarial infection modulates malaria-specific type 1 cytokine responses in an IL-10-dependent manner in a filaria/malaria-coinfected population.

Authors:  Simon Metenou; Benoit Dembélé; Siaka Konate; Housseini Dolo; Siaka Y Coulibaly; Yaya I Coulibaly; Abdallah A Diallo; Lamine Soumaoro; Michel E Coulibaly; Dramane Sanogo; Salif S Doumbia; Marissa Wagner; Sekou F Traoré; Amy Klion; Siddhartha Mahanty; Thomas B Nutman
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

3.  Haplotypes of IL12B promoter polymorphisms condition susceptibility to severe malaria and functional changes in cytokine levels in Thai adults.

Authors:  Chintana Phawong; Collins Ouma; Piyatida Tangteerawatana; Jarinee Thongshoob; Tom Were; Yuvadee Mahakunkijcharoen; Duangrurdee Wattanasirichaigoon; Douglas Jay Perkins; Srisin Khusmith
Journal:  Immunogenetics       Date:  2010-04-13       Impact factor: 2.846

4.  Vascular endothelial growth factor (VEGF) and lovastatin suppress the inflammatory response to Plasmodium berghei infection and protect against experimental cerebral malaria.

Authors:  Miriam Canavese; Andrea Crisanti
Journal:  Pathog Glob Health       Date:  2015-09-21       Impact factor: 2.894

5.  Expression microarray analysis implicates apoptosis and interferon-responsive mechanisms in susceptibility to experimental cerebral malaria.

Authors:  Fiona E Lovegrove; Sina A Gharib; Samir N Patel; Cheryl A Hawkes; Kevin C Kain; W Conrad Liles
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

Review 6.  A double-edged sword: the role of NKT cells in malaria and HIV infection and immunity.

Authors:  Sandhya Vasan; Moriya Tsuji
Journal:  Semin Immunol       Date:  2009-12-04       Impact factor: 11.130

Review 7.  Sequestration and tissue accumulation of human malaria parasites: can we learn anything from rodent models of malaria?

Authors:  Blandine Franke-Fayard; Jannik Fonager; Anneke Braks; Shahid M Khan; Chris J Janse
Journal:  PLoS Pathog       Date:  2010-09-30       Impact factor: 6.823

8.  Predominance of interferon-related responses in the brain during murine malaria, as identified by microarray analysis.

Authors:  Jenny Miu; Nicholas H Hunt; Helen J Ball
Journal:  Infect Immun       Date:  2008-02-25       Impact factor: 3.441

9.  Vitamin D inhibits the occurrence of experimental cerebral malaria in mice by suppressing the host inflammatory response.

Authors:  Xiyue He; Juan Yan; Xiaotong Zhu; Qinghui Wang; Wei Pang; Zanmei Qi; Meilian Wang; Enjie Luo; Daniel M Parker; Margherita T Cantorna; Liwang Cui; Yaming Cao
Journal:  J Immunol       Date:  2014-06-25       Impact factor: 5.422

10.  Schistosoma mansoni infection reduces the incidence of murine cerebral malaria.

Authors:  Judith H Waknine-Grinberg; Daniel Gold; Ariel Ohayon; Eliezer Flescher; Alina Heyfets; Michael J Doenhoff; Gabriele Schramm; Helmut Haas; Jacob Golenser
Journal:  Malar J       Date:  2010-01-05       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.